A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

The present invention relates to a method for in situ preparation of cyano-bridged coordination polymers as metal nanoparticles within a biocompatible reverse micellar system by mixing at least two reverse micellar systems, each one containing at least one metal salt precursor. The invention also relates to the stabilization of theses nanoparticles by using a biocompatible reverse micellar system. This system takes part of the synthesis as a nanoreactor which comprises at least an acylglycerol, a sterol, lecithin, ethanol and water for the preparation of stable cyano-bridged metal nanoparticles without any use of additional stabilizer agent.

The present invention relates to a method for in situ preparation of cyano-bridged coordination polymers as metal nanoparticles within a biocompatible reverse micellar system by mixing at least two reverse micellar systems, each one containing at least one metal salt precursor. The invention also relates to the stabilization of theses nanoparticles by using a biocompatible reverse micellar system. This system takes part of the synthesis as a nanoreactor which comprises at least an acylglycerol, a sterol, lecithin, ethanol and water for the preparation of stable cyano-bridged metal nanoparticles without any use of additional stabilizer agent.

A fullerene-metal nanocomposite is described that comprises a metal nanoparticle bonded to a functionalized fullerene compound. A useful method of making a fullerene-metal nanocomposite is also described. The method consists essentially of the steps of mixing a solution of metal salt or metal ion with a functionalized fullerene compound, and purifying the fullerene-metal nanocomposite from the solution. Also described are antimicrobial surfaces, comprising a substrate surface and a coating on the substrate surface comprising a fullerene-metal nanocomposite that includes a metal nanoparticle bonded to a functionalized fullerene compound.

Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

Described herein are compounds, compositions and methods for treatment of cancer. Also described are methods and uses for identifying subject with cancer that are suitable for treatment with the compounds, composition and methods are described herein. In one aspect of the present invention, there is provided a method of treating a subject having a cancer deficient in NMT2, comprising: administering to said subject an NMT inhibitor.

The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

The invention relates to a method for producing a composition containing at least one metal amino acid compound, in which method —a basic compound of a divalent metal is first reacted together with an alpha amino acid in a molar relationship of one to at least two in water during heating of up to 60° C. to 100° C., —a reaction equilibrium is awaited, —the reaction solution is then mixed with a water-soluble salt of the same divalent metal at a quantity such that the molar total quantity of the divalent metal from the basic compound of the metal and the metal salt does not exceed the molar quantity of the alpha amino acid, —the metal salt is allowed to completely dissolve, —the reaction solution is then dried thereby obtaining a solid composition.